MetrioPharm AG Investor Relations News
-
MetrioPharm Investor Relations News QIII 2018
Topics: Update on the ongoing Phase-II-study, MetrioPharm in Stockholm, Investor Talks in New York, Herbstkonferenz in Frankfurt, Company Calendar
-
MetrioPharm Investor Relations News QII 2018
Topics: 12th Annual General Meeting, Investor Talks in Munic, Swiss Biotech Day in Basel, MetrioPharm in Boston, SFRRI Meeting in Lisbon, Investor Talks in Dublin, Corporate Calendar
-
MetrioPharm Investor Relations News QI 2018
Topics: Greetings from Dr. Wolfgang Brysch, CEO of MetrioPharm AG, First Patient First Dose, MetrioPharm Blog, J.P. Morgen Healthcare Conference, Swiss Nordic Bio, Investor Talks in Monaco, Corporate Calendar
-
MetrioPharm Investor Relations News QIV 2017
Topics: End-of-the-year Review by CEO Dr. Wolfgang Brysch, Bio-Europe 2017 Berlin, German Equity Forum 2017, Investor Talks with MetrioPharm AG in New York, Company Calendar of MetrioPharm AG in QI 2018
-
MetrioPharm Investor Relations News QIII 2017
Topics: Filing of Phase II Study in Psoriasis Patients, 10th Anniversary of MetrioPharm AG, Extraordinary Annual General Meeting, Corporate Calendar of MetrioPharm AG
-
MetrioPharm Investor Relations News QII 2017
Topics: 11th Annual General Meeting, Letter to MetrioPharm Shareholders, German Biotechnology Days, Swiss Biotech Day, BioEquity Europe, Corporate Calendar of MetrioPharm AG
-
MetrioPharm Investor Relations News QI 2017
Topics: Phase IIa Results, JP Morgan Healthcare conference, BioEurope Spring, Corporate Calendar of MetrioPharm AG
-
Investor Relations News QIV 2016
Topics: End-of-the-year Review, Feedback on the Perception Study, MetrioPharm AG at German Equity Forum 2016, Financial Calender of MetrioPharm AG in QI 2017
-
Investor Relations News QIII 2016
Topics: Financial Calendar of MetrioPharm AG, Capital Increase, Investor Relations Perception Study, Current Status of MP1032’s Phase IIa in Psoriasis, About Us: Clinical Development.
-
10th Annual General Meeting of MetrioPharm AG
At the beginning, the Management and Board of MetrioPharm AG presented the 2015 annual financial statement and the progress of MetrioPharm's Research and Development projects.